Stock CRVS CORVUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.16 USD +2.37% Intraday chart for Corvus Pharmaceuticals, Inc. +4.85% +22.73%
May. 07 Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing MT
May. 07 Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing
MT
Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating
MT
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating
MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
MT
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target
MT
Ladenburg Thalmann Adjusts Corvus Pharmaceuticals Price Target to $10 From $4, Maintains Buy Rating
MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $4 From $2, Maintains Overweight Rating
MT
Ladenburg Thalmann Starts Corvus Pharmaceuticals at Buy with $2 Price Target
MT
Cantor Fitzgerald Adjusts Corvus Pharmaceuticals' Price Target to $4 from $8, Keeps Overweight Rating
MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $8 From $5, Maintains Overweight Rating
MT
Jefferies Reinstates Corvus Pharmaceuticals at Buy With $8 Price Target
MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $5 From $10, Maintains Overweight Rating
MT
CORVUS PHARMACEUTICALS : Mizuho Securities Adjusts Corvus Pharmaceuticals' Price Target to $3.50 From $4, Maintains Neutral Rating
MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Corvus Pharmaceuticals' Price Target to $6 from $9.50, Keeps Buy Rating
MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Starts Corvus Pharmaceuticals With Overweight Rating, $10 Price Target
MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Corvus Pharmaceuticals to $9.50 From $12, Maintains Buy Rating
MT
CORVUS PHARMACEUTICALS : Mizuho Downgrades Corvus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $7
MT
CORVUS PHARMACEUTICALS : Wedbush Adjusts Price Target on Corvus Pharmaceuticals to $6 From $8, Keeps Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRVS Stock
  4. News Corvus Pharmaceuticals, Inc.
  5. Analyst Reco.